<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595606</url>
  </required_header>
  <id_info>
    <org_study_id>03SHDD</org_study_id>
    <nct_id>NCT02595606</nct_id>
  </id_info>
  <brief_title>0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients</brief_title>
  <official_title>0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized parallel controlled study was designed to compare the efficacy of 0.3% Sodium
      Hyaluronate in the treatment of Dry Eye of diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ocular surface disease index</measure>
    <time_frame>up to 2 months</time_frame>
    <description>pre-,1,4,8 weeks after the initiation of the study(the use of drug for experimental group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tear break up time</measure>
    <time_frame>up to 2 months</time_frame>
    <description>BUT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer' test</measure>
    <time_frame>up to 2 months</time_frame>
    <description>test of tear secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conjunctival goblet cells density</measure>
    <time_frame>up to 2 months</time_frame>
    <description>indirect assessment of tear quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corneal fluorescein staining assessment</measure>
    <time_frame>up to 2 months</time_frame>
    <description>assessment of the corneal invasion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>without treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Sodium Hyaluronate</intervention_name>
    <description>five times per day for the intervention of eye drop</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. medical history of diabetes

          2. diagnosed with proliferative diabetic retinopathy

          3. diagnosed with dry eye

          4. not involvement in other drug experiment in the past 2 weeks

          5. vision acuity better than 0.1

          6. no local drug using history or with at least 2 weeks blanking period

        Exclusion Criteria:

          1. allergy to any of the drug ingredient

          2. being or going to be pregnant or in lactation period

          3. with any other eye disease or other serious disease which might affect the trial or
             could not get in follow-up

          4. with any eye surgery history in the past six months

          5. usage of hormone for replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang Xiulan, M.D.</last_name>
    <phone>02087335367</phone>
    <email>zhangxl2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Zhichong, M.D.</last_name>
      <phone>02087333391</phone>
      <email>wzc001@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gao Xinbo, M.D.</last_name>
      <phone>02087330484</phone>
      <email>936319557@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dogru M. Tear secretion and tear film function in insulin dependent diabetics. Br J Ophthalmol. 2000 Oct;84(10):1210.</citation>
    <PMID>11004112</PMID>
  </reference>
  <reference>
    <citation>Fujishima H, Shimazaki J, Yagi Y, Tsubota K. Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study. Cornea. 1996 Jul;15(4):368-75.</citation>
    <PMID>8776562</PMID>
  </reference>
  <reference>
    <citation>Zhivov A, Stachs O. Re: &quot;Increased Langerhan cell density and corneal nerve damage in diabetic patients: Role of immune mechanisms in human diabetic neuropathy&quot; by Tavakoli et al. Cont Lens Anterior Eye. 2011 Apr;34(2):98; author reply 99. doi: 10.1016/j.clae.2010.12.003. Epub 2011 Jan 6.</citation>
    <PMID>21215678</PMID>
  </reference>
  <reference>
    <citation>Maruyama K, Asai J, Ii M, Thorne T, Losordo DW, D'Amore PA. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol. 2007 Apr;170(4):1178-91.</citation>
    <PMID>17392158</PMID>
  </reference>
  <reference>
    <citation>Gao N, Yin J, Yoon GS, Mi QS, Yu FS. Dendritic cell-epithelium interplay is a determinant factor for corneal epithelial wound repair. Am J Pathol. 2011 Nov;179(5):2243-53. doi: 10.1016/j.ajpath.2011.07.050. Epub 2011 Sep 13.</citation>
    <PMID>21924232</PMID>
  </reference>
  <reference>
    <citation>Lu W, Ebihara N, Miyazaki K, Murakami A. Reduced expression of laminin-5 in corneal epithelial cells under high glucose condition. Cornea. 2006 Jan;25(1):61-7.</citation>
    <PMID>16331044</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Wang Zhichong</investigator_full_name>
    <investigator_title>cornea department chief</investigator_title>
  </responsible_party>
  <keyword>dry eye syndromes</keyword>
  <keyword>diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

